Vanguard Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-3,707,210
| Closed | -$74.7M | – | 4679 |
|
|
2021
Q3 | $74.7M | Buy |
3,707,210
+86,857
| +2% | +$2.4M | ﹤0.01% | 2150 |
|
|
2021
Q2 | $135M | Buy |
3,620,353
+52,708
| +1% | +$1.62M | ﹤0.01% | 1836 |
|
|
2021
Q1 | $91.2M | Buy |
3,567,645
+211,926
| +6% | +$5.41M | ﹤0.01% | 1999 |
|
|
2020
Q4 | $73.9M | Buy |
3,355,719
+116,657
| +4% | +$2.57M | ﹤0.01% | 1996 |
|
|
2020
Q3 | $58.3M | Sell |
3,239,062
-97,913
| -3% | -$2.03M | ﹤0.01% | 1931 |
|
|
2020
Q2 | $84.8M | Buy |
3,336,975
+385,118
| +13% | +$8.3M | ﹤0.01% | 1755 |
|
|
2020
Q1 | $54.2M | Buy |
2,951,857
+119,658
| +4% | +$2.33M | ﹤0.01% | 1840 |
|
|
2019
Q4 | $62.4M | Buy |
2,832,199
+276,927
| +11% | +$5.57M | ﹤0.01% | 1993 |
|
|
2019
Q3 | $36.7M | Buy |
2,555,272
+216,078
| +9% | +$3.09M | ﹤0.01% | 2215 |
|
|
2019
Q2 | $36.8M | Buy |
2,339,194
+35,905
| +2% | +$488K | ﹤0.01% | 2255 |
|
|
2019
Q1 | $33.7M | Sell |
2,303,289
-37,319
| -2% | -$429K | ﹤0.01% | 2277 |
|
|
2018
Q4 | $25M | Buy |
2,340,608
+357,336
| +18% | +$4.7M | ﹤0.01% | 2348 |
|
|
2018
Q3 | $30.3M | Buy |
1,983,272
+573,197
| +41% | +$8.34M | ﹤0.01% | 2383 |
|
|
2018
Q2 | $17.3M | Buy |
1,410,075
+179,675
| +15% | +$2.26M | ﹤0.01% | 2629 |
|
|
2018
Q1 | $11.8M | Buy |
1,230,400
+640,827
| +109% | +$6.91M | ﹤0.01% | 2753 |
|
|
2017
Q4 | $5.32M | Buy |
589,573
+152,908
| +35% | +$1.12M | ﹤0.01% | 3111 |
|
|
2017
Q3 | $2.51M | Buy |
436,665
+96,338
| +28% | +$351K | ﹤0.01% | 3335 |
|
|
2017
Q2 | $1.08M | Buy |
340,327
+14,517
| +4% | +$45.8K | ﹤0.01% | 3549 |
|
|
2017
Q1 | $1.11M | Buy |
325,810
+1,086
| +0.3% | +$3.06K | ﹤0.01% | 3553 |
|
|
2016
Q4 | $935K | Sell |
324,724
-163,161
| -33% | -$580K | ﹤0.01% | 3576 |
|
|
2016
Q3 | $2.87M | Sell |
487,885
-44,185
| -8% | -$155K | ﹤0.01% | 3250 |
|
|
2016
Q2 | $1.6M | Sell |
532,070
-16,622
| -3% | -$68.3K | ﹤0.01% | 3453 |
|
|
2016
Q1 | $2.94M | Buy |
548,692
+27,466
| +5% | +$173K | ﹤0.01% | 3219 |
|
|
2015
Q4 | $6.19M | Buy |
521,226
+36,511
| +8% | +$418K | ﹤0.01% | 2891 |
|
|
2015
Q3 | $3.98M | Buy |
484,715
+57,969
| +14% | +$669K | ﹤0.01% | 3074 |
|
|
2015
Q2 | $5.95M | Buy |
426,746
+128,145
| +43% | +$2.35M | ﹤0.01% | 2926 |
|
|
2015
Q1 | $7.18M | Buy |
298,601
+60,807
| +26% | +$1.37M | ﹤0.01% | 2813 |
|
|
2014
Q4 | $3.92M | Buy |
237,794
+42,554
| +22% | +$491K | ﹤0.01% | 3016 |
|
|
2014
Q3 | $2.49M | Buy |
195,240
+77,155
| +65% | +$1.16M | ﹤0.01% | 3169 |
|
|
2014
Q2 | $2.67M | Buy |
118,085
+50,364
| +74% | +$913K | ﹤0.01% | 3131 |
|
|
2014
Q1 | $1.91M | Buy |
+67,721
| New | +$2.52M | ﹤0.01% | 3246 |
|
Other funds holding DRNA
Vanguard Group's DRNA Position: Q4 2021 in Review
Vanguard Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 3,707,210 shares — an estimated $74.7M sold.
Vanguard Group first reported a position in DRNA in Q1 2014 and held it in 31 quarters. The position peaked at $135M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Vanguard Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Vanguard Group sold 3,707,210 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $74.7M.
- Vanguard Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 31 quarters.
- Vanguard Group's Dicerna Pharmaceuticals, Inc. position peaked at $135M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Vanguard Group's 13F filing for Q4 2021, filed 14 Feb 2022.